A study indicates that men who utilize medications for erectile dysfunction, such as Viagra, might lower their susceptibility to Alzheimer’s disease.
Findings from research involving over 260,000 men suggest that those who use these medications are 18% less prone to developing the dementia-inducing condition.
However, further investigation is necessary to establish a causal relationship between the drugs and this effect.
- California RESIDENTS To RECEIVE $500 MONTHLY PAYMENTS In New Guaranteed Income Program: Here Is Who Is Eligible
- Us Job Market Booms With 272,000 New Jobs, But Unemployment Rises Slightly To 4.0%
- Credit Scores Of 720+ See Improved Loan Rates This Week
- Examining The Facts: Fact Check On IRS $8700 Stimulus Check Eligibility & Payment Dates
- Gas Prices On Downward Trend As Fourth Of July Road Trips Approach: AAA
Furthermore, two newly developed drugs for Alzheimer’s have exhibited significant potential in slowing the progression of the disease during its initial phases.
These drugs function by targeting a substance known as beta amyloid, which accumulates in the brains of individuals with Alzheimer’s, potentially revolutionizing the approach to treating the disease.
Nevertheless, researchers are also persisting in their search for existing medications capable of either preventing or delaying the onset of Alzheimer’s disease altogether.
Viagra-Like Drugs: Heart to Brain Influence
Medications akin to Viagra were initially formulated to address hypertension and angina, functioning by modulating a cell-signaling agent that potentially intersects with memory processes.
Additionally, they are recognized for their influence on brain cell function, with animal studies indicating a potential neuroprotective role.
In a recent investigation published in Neurology, scholars from University College London analyzed prescription data pertaining to numerous men grappling with erectile dysfunction, discerning disparities between those administered the medications and those who were not.
Over the subsequent five-year period, the researchers observed a rate of 8.1 Alzheimer’s cases per 10,000 person-years among individuals prescribed the medications, compared to 9.7 cases in those not receiving such prescriptions.
Notably, men who received the highest number of prescriptions for erectile dysfunction drugs demonstrated the lowest likelihood of Alzheimer’s development, implying a potential correlation between regular drug utilization and disease mitigation.
The researchers clarify that their study does not definitively establish a causal relationship between the drugs and decreased Alzheimer’s risk but instead suggests a prospective avenue for further investigation.